BernsteinW.B., CoxJ.H., AronsonN.E., et al. (2004). Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons. Clin. Immunol., 111, 262–274.
2.
BrentjensR.J., LatoucheJ.B., SantosE., et al. (2003). Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med., 9, 279–286.
3.
BretscherP., and CohnM. (1970). A theory of self-nonself discrimination. Science, 169, 1042–1049.
4.
CameronB.J., GerryA.B., DukesJ., et al. (2013). Identification of a titin-derived HLA-A1–presented peptide as a cross-reactive target for engineered MAGE A3–directed T cells. Sci. Transl. Med., 5, 197ra103.
5.
CarpenitoC., MiloneM.C., HassanR., et al. (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA, 106, 3360–3365.
6.
CarrollR.G., RileyJ.L., LevineB.L., et al. (1997). Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science, 276, 273–276.
7.
CooperL.J., ToppM.S., SerranoL.M., et al. (2003). T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood, 101, 1637–1644.
8.
DeeksS.G., WagnerB., AntonP.A., et al. (2002). A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination anti-retroviral therapy. Mol. Ther., 5, 788–797.
9.
DullT., ZuffereyR., KellyM., et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol., 72, 8463–8471.
10.
EshharZ, WaksT, GrossG, SchindlerDG. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. U S A, 90, 720–724.
11.
FrenkelN., SchirmerE.C., KatsafanasG., and JuneC.H. (1990a). T-cell activation is required for efficient replication of human herpesvirus 6. J. Virol., 64, 4598–4602.
12.
FrenkelN., SchirmerE.C., WyattL.S., et al. (1990b). Isolation of a new herpesvirus from human CD4+ T cells. Proc. Natl. Acad. Sci. USA, 87, 748–752.
13.
FriedmannT. (1992). A brief history of gene therapy. Nat. Genet., 2, 93–98.
14.
FriedmannT., and RoblinR. (1972). Gene therapy for human genetic disease?. Science, 175, 949–955.
15.
GattinoniL., LugliE., JiY., et al. (2011). A human memory T cell subset with stem cell-like properties. Nat. Med., 17, 1290–1297.
16.
GladwellM. (2008). Outliers: The Story of Success. (Little, Brown and Company, New York, NY).
17.
GruppS.A., KalosM., BarrettD., et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med., 368, 1509–1518.
18.
IrvingB.A., and WeissA. (1991). The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell, 64, 891–901.
19.
JuneC.H., and RabinovitchP.S. (1990). Flow cytometric measurement of intracellular ionized calcium in single cells with indo-1 and fluo-3. In Methods in Cell Biology. WilsonL., ed. (Academic Press, Inc., San Diego, CA) pp. 37–58.
20.
JuneC.H., ContrerasC.E., PerrinL.H., and LambertP.H. (1979a). Improved detection of immune complexes in human and mouse serum using a microassay adaptation of the C1q binding test. J. Immunol. Methods, 31, 23–29.
21.
JuneC.H., ContrerasC.E., PerrinL.H., et al. (1979b). Circulating and tissue-bound immune complex formation in murine malaria. J. Immunol., 122, 2154–2161.
22.
JuneC.H., ThompsonC.B., KennedyM.S., et al. (1985). Profound hypomagnesemia and renal magnesium wasting associated with the use of cyclosporine for marrow transplantation. Transplantation, 39, 620–624.
23.
JuneC.H., LedbetterJ.A., RabinovitchP.S., et al. (1986a). Distinct patterns of transmembrane calcium flux and intracellular calcium mobilization after differentiation antigen cluster 2 (E rosette receptor) or 3 (T3) stimulation of human lymphocytes. J. Clin. Invest., 77, 1224–1232.
24.
JuneC.H., ThompsonC.B., KennedyM.S., et al. (1986b). Correlation of hypomagnesemia with the onset of cyclosporine- associated hypertension in marrow transplant patients. Transplantation, 41, 47–51.
25.
JuneC.H., LedbetterJ.A., GillespieM.M., et al. (1987). T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell Biol., 7, 4472–4481.
26.
JuneC.H., LedbetterJ.A., LindstenT., and ThompsonC.B. (1989). Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes. J. Immunol., 143, 153–161.
27.
JuneC.H., LedbetterJ.A., LinsleyP.S., and ThompsonC.B. (1990). Role of the CD28 receptor in T-cell activation. Immunol. Today, 11, 211–216.
28.
JuneC.H., LinetteG.P., PierceP.F., et al. (1993). Potential clinical applications of signal transduction measurements in marrow transplantation and HIV-1 infection. Ann. N.Y. Acad. Sci., 677, 225–232.
29.
KalosM., LevineB.L., PorterD.L., et al. (2011). T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia. Sci. Transl. Med., 3, 95ra73.
LaportG.G., LevineB.L., StadtmauerE.A., et al. (2003). Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood, 102, 2004–2013.
32.
LedbetterJ.A., GentryL.E., JuneC.H., et al. (1987). Stimulation of T cells through the CD3/T-cell receptor complex: role of cytoplasmic calcium, protein kinase C translocation, and phosphorylation of pp60 c-src in the activation pathway. Mol. Cell Biol., 7, 650–656.
33.
LetourneurF., and KlausnerR.D. (1991). T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc. Natl. Acad. Sci. USA, 88, 8905–8909.
34.
LevineB.L., MoscaJ., RileyJ.L., et al. (1996). Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science, 272, 1939–1943.
35.
LevineB.L., BernsteinW., CraigheadN., et al. (1997). Effects of CD28 costimulation on long term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol., 159, 5921–5930.
36.
LevineB.L., CotteJ., SmallC.C., et al. (1998). Large scale production of CD4+ T cells from HIV-infected donors following CD3/CD28 stimulation. J. Hematother., 7, 437–448.
37.
LevineB.L., BernsteinW.B., AronsonN.E., et al. (2002). Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat. Med., 8, 47–53.
38.
LevineB.L., HumeauL.M., BoyerJ., et al. (2006). Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA, 103, 17372–17377.
39.
LinetteG.P., HartzmanR.J., LedbetterJ.A., and JuneC.H. (1988). HIV-1-infected T cells show a selective signaling defect after perturbation of CD3/antigen receptor. Science, 241, 573–576.
40.
LinetteG.P., StadtmauerE.A., MausM.V., et al. (2013). Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood, 122, 863–871.
41.
LiuK., SchoonmakerM.M., LevineB.L., et al. (1999). Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc. Natl. Acad. Sci. USA, 96, 5147–5152.
42.
MartinP.J., LedbetterJ.A., MorishitaY., et al. (1986). A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. J. Immunol., 136, 3282–3287.
43.
MaudeS., FreyN., ShawP., et al. (2014). Sustained remissions with chimeric antigen receptor T cells for leukemia. N. Engl. J. Med. In press.
44.
MausM.V., ThomasA.K., LeonardD.G., et al. (2002). Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol., 20, 143–148.
45.
MausM.V., KovacsB., KwokW.W., et al. (2004). Extensive replicative capacity of human central memory T cells. J. Immunol., 172, 6675–6683.
46.
MausM.V., GruppS.A., PorterD.L., and JuneC.H. (2014). Antibody modified T cells: CARs take the front seat for hematologic malignancies. Blood, 123, 2625–2635.
47.
MiloneM.C., FishJ.D., CarpenitoC., et al. (2009). Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther., 17, 1453–1464.
48.
MitsuyasuR.T., AntonP., DeeksS.G., et al. (2000). Prolonged survival and tissue trafficking following adoptive transfer of CD4 z gene-modified autologous CD4+ and CD8+ T cells in HIV-infected subjects. Blood, 96, 785–793.
49.
Nelson-ReesW.A., DanielsD.W., and FlandermeyerR.R. (1981). Cross-contamination of cells in culture. Science, 212, 446–452.
50.
PalmerL.D., WengN.P., LevineB.L., et al. (1997). Telomere length, telomerase activity, and replicative potential in HIV infection: analysis of CD4+ and CD8+ T cells from HIV-discordant monozygotic twins. J. Exp. Med., 185, 1381–1386.
51.
PerezE.E., WangJ., MillerJ.C., et al. (2008). Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol., 26, 808–816.
52.
PorterD.L., LevineB.L., KalosM., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med., 365, 725–733.
53.
RabinovitchP.S., JuneC.H., GrossmannA., and LedbetterJ.A. (1986). Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. J. Immunol., 137, 952–961.
54.
RapoportA.P., LevineB.L., BadrosA., et al. (2004). Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant., 33, 53–60.
55.
Rerks-NgarmS., PitisuttithumP., NitayaphanS., et al. (2009). Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N. Engl. J. Med., 361, 2209–2220.
56.
RileyJ.L., CarrollR.G., LevineB.L., et al. (1997). Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. J. Immunol., 158, 5545–5553.
57.
RoessigC., SchererS.P., BaerA., et al. (2002). Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann. Hematol., 81Suppl 2, S42–S43.
58.
RomeoC., and SeedB. (1991). Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell, 64, 1037–1046.
59.
SchollerJ., BradyT., Binder-SchollG., et al. (2012). Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med., 4, 132Ra53.
60.
StorbR., DeegH.J., WhiteheadJ., et al. (1986). Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N. Engl. J. Med., 314, 729–735.
61.
SuhoskiM.M., GolovinaT.N., AquiN.A., et al. (2007). Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol. Ther., 15, 981–988.
62.
TebasP., SteinD., TangW., et al. (2014). Gene editing of CCR5 in autologous CD4 T-cells of persons infected with HIV. N. Engl. J. Med., 370, 901–910.
63.
ThompsonC.B., JuneC.H., SullivanK.M., and ThomasE.D. (1984). Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet, 2, 1116–1120.
64.
ThompsonC.B., LindstenT., LedbetterJ.A., et al. (1989). CD28 activation pathway regulates the production of multiple T- cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA, 86, 1333–1337.
65.
WalkerR.E., BechtelC.M., NatarajanV., et al. (2000). Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood, 96, 467–474.
66.
WangG.P., LevineB.L., BinderG.K., et al. (2009). Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol. Ther., 17, 844–850.
67.
WengN.P., LevineB.L., JuneC.H., and HodesR.J. (1995). Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc. Natl. Acad. Sci. USA, 92, 11091–11094.
68.
WengN.P., LevineB.L., JuneC.H., and HodesR.J. (1996). Regulated expression of telomerase activity in human T lymphocyte development and activation. J. Exp. Med., 183, 2471–2480.
